Research & Access Updates

— Wednesday, February 10, 2021

Real‐world outcomes with bortezomib‐containing regimens and lenalidomide plus dexamethasone for the treatment of transplant‐ineligible multiple myeloma

Extract o the report: Bortezomib‐containing regimens (BCRs) represented standard, first‐line therapy f...

Read more

— Monday, January 25, 2021

Myeloma Canada invests a yearly record-high $735,000 in Canadian myeloma research projects

Myeloma Canada invested in more important research initiatives in 2020 than in any other year, thanks to...

Read more

— Thursday, December 10, 2020

Inaugural Coverage of the 62nd ASH Annual Meeting & Exposition by the CMRG.

Take a look at this all-virtual 4-day event recap, with a 90-minute panel discussion on the CMRG YouTube...

Read more

— Thursday, November 26, 2020

Canadian perspective on managing multiple myeloma during the COVID-19 pandemic: lessons learned and future considerations

The coronavirus disease 2019 (covid-19) pandemic caused by the novel severe acute respiratory syndrome co...

Read more

— Friday, October 9, 2020

Nirogacestat in Combination with PF‐06863135 in Patients with Relapsed or Refractory Multiple Myeloma

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on deve...

Read more

— Monday, September 28, 2020

Triplet Regimens Dominate the Relapsed/Refectory Myeloma Treatment Landscape

Novel triplet combinations are leading the key developments made in the treatment of patients with relaps...

Read more